Home/ Supplements/ Ginkgo
Compound

Ginkgo

Also known as egb761, ginkgo biloba, ginkgo extract, maidenhair tree

183 Research sources
99/100 Market safety
120.0 mg Median dose
476 Products on market

Key takeaways

  • Cochrane meta-analyses indicate a lack of consistent evidence for Ginkgo in treating cognitive impairment and dementia (PMID: 41641880, PMID: 19160216).
  • Evidence for the use of Ginkgo biloba in treating tinnitus is insufficient to support its use (PMID: 23543524, PMID: 36383762).
  • Ginkgo biloba has been evaluated for efficacy in acute ischemic stroke patients (PMID: 32349519).
Evidence

What the research shows

AI-synthesized from 183 peer-reviewed sources · Updated 2025

Ginkgo biloba is a herbal supplement widely used for cognitive enhancement and the treatment of dementia and circulatory issues. While numerous meta-analyses and systematic reviews exist, the overall evidence for its efficacy in treating cognitive impairment and dementia remains inconsistent and often inconclusive.

By condition

Cognitive Impairment and Dementia Weak
Large-scale Cochrane reviews and meta-analyses indicate limited or inconsistent evidence for its effectiveness in treating or preventing cognitive decline.

Tinnitus Insufficient
Systematic reviews suggest that Ginkgo biloba does not provide a significant benefit for the treatment of tinnitus.

Intermittent Claudication Weak
Meta-analyses of Ginkgo for intermittent claudication have generally failed to show a definitive clinical benefit.

Acute Ischemic Stroke Moderate
Some evidence suggests potential efficacy and safety when used in patients with acute ischemic stroke.

Effective doses

Specific effective dose ranges were not provided in the provided study abstracts.

Safety & interactions

Safety data is mentioned in several reviews; however, specific contraindications (such as bleeding risks) should be verified via regulatory sources or clinical guidelines.

Limitations

Research is characterized by a high volume of systematic reviews but a lack of recent, high-powered RCTs to definitively prove efficacy. Many studies show conflicting results across different populations.

Products

Top-rated Ginkgo products

Ranked by safety score and evidence coverage

View all 476 products →
Interactions

Drug–supplement interactions

99 documented interactions

DrugSeverityMechanismEvidence
Digoxin Critical Ginkgo is a moderate inhibitor of P-gp, which decreases metabolism of P-gp subst cyp-inferred
GI Prokinetics Critical Ginkgo is a weak inhibitor of CYP3A4, which decreases metabolism of CYP3A4 subst cyp-inferred
Immunosuppressants Critical Ginkgo is a weak inhibitor of CYP3A4, which decreases metabolism of CYP3A4 subst cyp-inferred
ADHD Medications Moderate Ginkgo is a weak inhibitor of CYP2D6, which decreases metabolism of CYP2D6 subst cyp-inferred
Abciximab Moderate Interaction identified from DDInter 2.0 database. Specific drugs: Abciximab ddinter-verified
Aldesleukin Moderate Interaction identified from DDInter 2.0 database. Specific drugs: Aldesleukin ddinter-verified
Alimemazine Moderate Interaction identified from DDInter 2.0 database. Specific drugs: Alimemazine ddinter-verified
Alteplase Moderate Interaction identified from DDInter 2.0 database. Specific drugs: Alteplase ddinter-verified
Aminophylline Moderate Interaction identified from DDInter 2.0 database. Specific drugs: Aminophylline ddinter-verified
Analgesics Moderate Ginkgo is a weak inducer of CYP1A2, which increases metabolism of CYP1A2 substra cyp-inferred
Marketplace

How it's sold

Data aggregated from 476 product labels

Forms
Top brands
Claims vs evidence
100% Evidence-backed
80% Structure/function
0% Unsupported
Sources

Research evidence

Showing top 10 of 183 sources, sorted by quality

Meta Analysis· The Cochrane database of systematic reviews· 2026· n=10613· PMID 41641880

**Wieland et al., 2026** | Cochrane Database Syst Rev | Meta Analysis Wieland Lisa S, Ludeman Emilie, ... Amri Hakima. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2026-Feb-05;2(2):CD013661. doi:10.1002/1…

Meta Analysis· The Cochrane database of systematic reviews· 2009· n=2016· PMID 19160216

**Birks et al., 2009** | Cochrane Database Syst Rev | Meta Analysis Birks Jacqueline, Grimley Evans John. Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev. 2009-Jan-21(1):CD003120. doi:10.1002/14651858.CD00312…

Meta Analysis· The Cochrane database of systematic reviews· 2013· n=1543· PMID 23543524

**Hilton et al., 2013** | Cochrane Database Syst Rev | Meta Analysis Hilton Malcolm P, Zimmermann Eleanor F, Hunt William T. Ginkgo biloba for tinnitus. Cochrane Database Syst Rev. 2013-Mar-28;2013(3):CD003852. doi:10.1002/14651858.CD003852…

Systematic Review· The Cochrane database of systematic reviews· 2022· n=1915· PMID 36383762

**Sereda et al., 2022** | Cochrane Database Syst Rev | Systematic Review Sereda Magdalena, Xia Jun, ... Hoare Derek J. Ginkgo biloba for tinnitus. Cochrane Database Syst Rev. 2022-Nov-16;11(11):CD013514. doi:10.1002/14651858.CD013514.pub2 B…

Rct· JAMA· 2008· n=2587· PMID 19017911

CONTEXT: Ginkgo biloba is widely used for its potential effects on memory and cognition. To date, adequately powered clinical trials testing the effect of G. biloba on dementia incidence are lacking. OBJECTIVE: To determine effectiveness of…

Systematic Review· Frontiers in aging neuroscience· 2023· n=1642· PMID 36960422

OBJECTIVE: To conduct a meta-analysis of the effectiveness and safety of ginkgo biloba preparations combined with donepezil hydrochloride vs. donepezil for the treatment of Alzheimer's disease (AD). METHODS: Three English databases (Cochran…

Meta Analysis· The Cochrane database of systematic reviews· 2013· n=739· PMID 23744597

**Nicolaï et al., 2013** | Cochrane Database Syst Rev | Meta Analysis Nicolaï Saskia P A, Kruidenier Lotte M, ... Teijink Joep A W. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev. 2013-Jun-06;2013(6):CD006888. doi:1…

Systematic Review· Frontiers in aging neuroscience· 2020· n=6863· PMID 32581760

**Lai et al., 2020** | Front Aging Neurosci | Systematic Review Lai Xin, Wen Hao, ... Tang Chunzhi. The Comparative Efficacy of Multiple Interventions for Mild Cognitive Impairment in Alzheimer's Disease: A Bayesian Network Meta-Analysis. F…

Meta Analysis· Phytomedicine : international journal of phytotherapy and phytopharmacology· 2026· n=2107· PMID 41678913

**Tiemtad et al., 2026** | Phytomedicine | Meta Analysis Tiemtad Pailada, Ingkaninan Kornkanok, ... Dhippayom Teerapon. Comparative effects of Bacopa monnieri and Ginkgo biloba on cognitive functions: A systematic review and network meta-an…

Meta Analysis· The Cochrane database of systematic reviews· 2009· n=739· PMID 19370657

**Nicolaï et al., 2009** | Cochrane Database Syst Rev | Meta Analysis Nicolaï Saskia P A, Kruidenier Lotte M, ... Teijink Joep A W. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev. 2009-Apr-15(2):CD006888. doi:10.100…

FAQ

Frequently asked questions

What is Ginkgo biloba and what is it commonly used for?

Ginkgo biloba is a herbal supplement widely used for cognitive enhancement, treating dementia, and addressing circulatory issues. While it is popular for these purposes, the overall evidence for its efficacy in treating cognitive impairment and dementia remains inconsistent and often inconclusive.

Does Ginkgo work for dementia or cognitive decline?

Research on Ginkgo for dementia and cognitive impairment is limited, with large-scale Cochrane reviews indicating weak evidence for its effectiveness. Consequently, the evidence is considered inconsistent, and it is not definitively proven to prevent or treat cognitive decline.

Is Ginkgo effective for treating tinnitus?

The evidence for using Ginkgo biloba to treat tinnitus is insufficient to support its use. Systematic reviews suggest that it does not provide a significant benefit for this condition.

Can Ginkgo help with intermittent claudication?

Meta-analyses regarding Ginkgo for intermittent claudication have generally failed to show a definitive clinical benefit, resulting in weak evidence for its efficacy in this area.

Are there any serious drug interactions with Ginkgo?

Yes, Ginkgo has moderate interaction risks with several medications. It may increase bleeding risk when taken with antiplatelet drugs or warfarin, and it may lower the seizure threshold when used with anticonvulsants.

Who should avoid taking Ginkgo biloba?

Individuals taking blood thinners, anticonvulsants, SSRIs, or trazodone should avoid Ginkgo due to potential interactions like increased bleeding or excessive sedation. Pregnant individuals and those with bleeding disorders should also consult a healthcare provider before use.

Is there evidence Ginkgo helps with acute ischemic stroke?

There is moderate evidence suggesting potential efficacy and safety for Ginkgo biloba in patients with acute ischemic stroke. However, specific effective doses were not provided in the available research summaries.